SHR-1603

N/A

Report date: 2022/09/23 20:01:17

Base Information

Drug NameSHR-1603
Drug Alias NameSHR-1603注射液SHR-1603
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsHematologic NeoplasmsLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co LtdJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsHematologic NeoplasmsLymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A